PlumX Metrics
Embed PlumX Metrics

Combination thymosin α and lymphoblastoid interferon treatment in chronic hepatitis C

Gut, ISSN: 0017-5749, Vol: 39, Issue: 5, Page: 679-683
1996
  • 52
    Citations
  • 0
    Usage
  • 11
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

Background - Monotherapy for chronic hepatitis C using interferon (IFN) results in a very small proportion of patients exhibiting a sustained response. Clinical trials assessing the benefit of combination drug therapy may provide evidence of improved treatment response over that seen with single drug treatment. Aim - To assess the response in patients with chronic hepatitis C to one year of combination treatment: thymosin α (Tα), 1 mg twice weekly, and lymphoblastoid (L)-IFN, 3 MU thrice weekly. Patients and Methods - Fifteen patients with serum HCV RNA positive chronic hepatitis C were studied. Eleven patients were treatment naive and four had failed previous standard IFN therapy. Thirteen patients were HCV RNA serotype 1b. All patients were given combination Tα and L-IFN therapy for one year with a six month follow up period. Results - Six months after initiation of treatment seven patients (47%) were sera HCV RNA negative and at completion of the one year treatment 11 (73%), including two who had failed previous standard IFN treatment, had negative serum HCV RNA. Six months after treatment, six patients (40%), including five with HCV type 1b, showed a sustained response characterised by a negative serum HCV RNA. Conclusions - The results of this open label trial suggest that there may be a potential benefit to combining an immune modulator (Tα) with an antiviral (IFN) in the treatment of chronic hepatitis C. Verification of the observations in this study require completion of a randomised controlled study.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know